Larofen Plus

Pseudoephedrine Hydrochloride, the active ingredient in Larofen Plus, is a combination decongestant and nonsteroidal anti‑inflammatory drug (NSAID) presented as an oral tablet for oral use. It helps relieve nasal congestion, headache, fever and general pain in adults and adolescents when prescribed by a healthcare professional.

GNH USA supplies Larofen Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Larofen Plus combines a nasal decongestant with an NSAID, addressing conditions where inflammation and congestion coexist.

- Nasal congestion: reduces swelling of nasal passages to improve airflow. - Headache: alleviates pain by decreasing prostaglandin‑mediated inflammation. - Fever: lowers elevated body temperature through antipyretic action. - General pain: provides analgesia for musculoskeletal or mild to moderate pain.

Common side effects are generally mild and transient.

Common Side Effects: - Nausea: mild stomach upset. - Dizziness: sensation of light‑headedness. - Insomnia: difficulty falling or staying asleep. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or breathing difficulty. - Gastrointestinal bleeding: black stools or vomiting blood. - Hypertension: significant rise in blood pressure.

Before using Larofen Plus, consider the following safety measures.

- Cardiovascular assessment: evaluate blood pressure and heart disease history. - Renal caution: adjust use in patients with impaired kidney function. - Gastro‑intestinal risk: avoid in individuals with active ulcers or bleeding disorders. - Drug combination warning: do not combine with other sympathomimetics or NSAIDs without medical advice. - Pregnancy and lactation: consult a healthcare professional before use. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Larofen Plus may interact with several medication classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other sympathomimetic agents: excessive vasoconstriction. - Anticoagulants (e.g., warfarin): increased bleeding risk. - Additional NSAIDs: heightened gastrointestinal toxicity.

Moderate Interactions (Monitor Closely):\n- Antihypertensives: possible reduction in blood‑pressure control. - Selective serotonin reuptake inhibitors (SSRIs): modest increase in bleeding tendency. - Diuretics: potential for electrolyte imbalance, especially potassium.